Goetz MP, O'Shaughnessy J, Sledge Jr., et al. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies. SABCS 2017, GS6-02.
Commissie voor Beentumoren nog steeds onmisbaar
apr 2022 | Bot en wekedelentumoren, Orthopedie